Asthma is a heterogeneous inflammatory airway disease, and up to 50% of patients exhibit a non-Th2 phenotype characterized by neutrophilic inflammation and poor responsiveness to glucocorticoids. This glucocorticoid-resistant phenotype represents a major unmet clinical need, yet current preclinical models do not adequately capture its underlying mechanisms. To address this gap, GemPharmatech developed a murine model of neutrophilic asthma induced by combined exposure to lipopolysaccharide (LPS) and house dust mite (HDM). This model recapitulates key features of the phenotype, including airway neutrophilia, macrophage infiltration, and airway remodeling, and demonstrates resistance to dexamethasone treatment, reflecting glucocorticoid-refractory asthma. It provides a reproducible platform for studying neutrophilic asthma and supporting the development of precision therapies.